Results:
The study was undertaken between April 2011 and May 2015. Six hundred patients were randomly assigned to SPC (n ¼ 297) and MPC (n ¼ 303), and were eligible for analyses. Thirteen patients (4.7%) in the SPC group experienced complications within 60 days after surgery, compared with 16 (6.1%) in the MPC group (p ¼ 0.468); however, single access procedures took longer (70 min vs. 55 min ; p 5 0.001). No difference in hospital stay and perception of pain was observed. Six patients experienced an incisional hernia at 1 year in the SPC group, compared with three in the MPC group (p ¼ 0.331). While patients better appreciated their cosmetic results in the SPC group, plastic surgeons were in favour of the cosmetic results in the MPC group. No difference in Quality of Life score was assessed by GIQLI at 60 days was observed. Conclusion: In selected patients with benign gall bladder disease requiring cholecystectomy, single access technique is non-inferior to standard laparoscopy in terms of safety, despite a longer operative time required. While concerns about possible increase of risk of incisional hernias following SPC are not justified, cosmetic results were perceived better in the single access technique. Disclosure of Interest: All authors have declared no conflicts of interest.
LB04 IMPACT OF COMORBIDITY AND PRESCRIPTION DRUGS ON HAEMORRHAGE IN CHOLECYSTECTOMY
J. Stro¨mberg, G. Sandblom Stockholm/SE Contact E-mail Address: stromberg10000@gmail.com Introduction: The influence of comorbidity on haemorrhagic complications in cholecystectomy is insufficiently known. Furthermore, the need for cessation of prescription drugs in order to reduce haemorrhagic complications is still a matter of debate. Aims & Methods: All cholecystectomies registered in the Swedish populationbased Register for Gallstone Surgery and ERCP (GallRiks) were identified. The effect of comorbidity and prescribed drugs on bleeding was assessed by linking data in the GallRiks to the National Patient Register and the Prescribed Drug Register respectively. The risk for haemorrhage leading to intervention was determined by variable regression, and Kaplan-Meier analysis assessed survival rate following perioperative haemorrhage. Results: A total of 94,557 patients were included between 2005 and 2015, of which 799 (0.8%) and 1192 (1.3%) patients were registered as having perioperative and postoperative haemorrhage, respectively. An increased risk for haemorrhagic complications was seen in patients with kidney disease, previous myocardial infarction, heart failure, cerebrovascular disease and obesity (all p 5 0.05). Prescription of tricyclic antidepressant or dipyridamole was associated with a significantly increased risk for perioperative haemorrhage (p 5 0.05). However, this increase in risk did not remain significant following Bonferroni correction for mass significance. Perioperative haemorrhage increased the risk of death occurring within the first postoperative year [Hazard Ratio, (HR): 4.9, CI: 3.52-6.93] as well as bile duct injury (OR: 2.45, CI: 1.79-3.37). Conclusion: The increased risk for haemorrhage associated with comorbidity must be taken into account when assessing patients prior to cholecystectomy. Perioperative bleeding increases postoperative mortality and is associated with an increased risk for bile duct injury. Amsterdam/NL, 2 Rotterdam/NL Contact E-mail Address: r.j.coelen@amc.nl Introduction: The Mayo Clinic recently presented a new staging system that is applicable to all patients with perihilar cholangiocarcinoma (PHC) regardless of subsequent treatment. 1 The staging system assigns patients to one of four stages, depending on the patients' performance status, serum CA19-9 level, and radiological parameters including tumor size, suspected vascular involvement, and metastatic disease. We aimed to validate this staging system. Aims & Methods: All consecutive patients with PHC who were evaluated and treated in two tertiary centers between January 2002 and December 2014 were identified. Baseline characteristics required for the prognostic model were collected from medical records and imaging parameters were reassessed by experienced abdominal radiologists. Overall survival (OS) was analyzed using the Kaplan-Meier method and comparison of staging groups was performed using the log-rank test and Cox proportional hazard regression analysis. Discriminative performance was quantified by the concordance (C)-index. Subgroup analysis was performed for treatment subgroups.
Results: A total of 600 patients were staged according to the Mayo Clinic model, allocating 23, 80, 357 and 140 patients to stages I, II, III and IV, respectively. Median OS was 11.6 months. Median OS of stages I, II, III and IV was 33. 2, 19.7, 12.1 and 6 .0 months, with hazard ratios (95% confidence interval) of 1.0 (reference), 2.02 (1.14-3.58 ), 2.71 (1.59-4.64 ) and 4.00 (2.30-6.95 ), respectively (p 5 0.001). The C-index (95% CI) was 0.59 (0.56-0.61) for the entire cohort. Statistically significant prognostic stratification was also observed in the laparotomy subgroup (p ¼ 0.011). Conclusion: The Mayo Clinic staging system for patients with PHC demonstrated stratification in four stages that differed significantly in median survival.
As the discriminative performance of the model was moderate, it may require improvement prior to clinical implementation. (TPCS2a) is a proprietary photosensitiser that is used to induce PCI. It is designed to localise to endosomal membranes and induce endosomal disruption upon light activation. Many cancer drugs and other molecules of therapeutic interest may end up entrapped in endosomes. PCI can induce the release of such molecules from the endosomes, thereby enabling them to reach their therapeutic target in the cell cytosol or nucleus. Based on positive preclinical results for PCI and gemcitabine and promising results from the first in man study with PCI in patients with various solid tumours, 1,2 it was decided to start a phase I/II study to investigate the effect of PCI with gemcitabine in patients with advanced inoperable perhilar CCA. The aim of this study was to establish the safety and tolerability of PCI with gemcitabine followed by standard systemic chemotherapy. The study was conducted at several centers in Germany, Norway and UK. Local radiological assessments were performed in phase I. A retrospective independent radiological evaluation was performed for the last two dose cohorts, to verify promising early signs of efficacy.
Results: A total of 16 patients were treated in the dose escalating Phase I part of this study. Four different dose cohorts were tested. The last patient completed the 6-month follow-up period in September 2016. Of the 16 patients treated, 11 completed the eight cycles of combination therapy, and five patients were early withdrawals. No patients expired while still on study. The treatment was well tolerated with no DLTs, and no serious safety concerns were raised. In the last two dose cohorts, independent radiological evaluation showed that seven out of eight patients had evaluable tumour, and four of these showed an objective tumour response at 6 months, including two complete responses. Conclusion: The patient number in this clinical study is small, but the results indicate high durable objective tumour response rates. The early signs of efficacy using PCI treatment with fimaporfin and gemcitabine are encouraging. The aim was to investigate the effect of FMT on the symptoms and on modifying the gut microbiota in patients with IBS. The study included 13 patients (four females and nine males, age range 20-44 years) with diarrhea-predominant IBS (IBS-D) according to Rome III criteria and 13 healthy asymptomatic donors. The patients received freshly donated feces from a relative and was administered in to the descending part of the duodenum via a gastroscope. Feces were collected from the donors and the patients before FMT and again from the patients after 1 week and 3 weeks. The samples were stored in freezers (-80 C) until analysis. Microbiota analysis was performed using the GA-map Dysbiosis test (Genetic Analysis AS, Oslo, Norway) by algorithmically assessing fecal bacterial abundance and profile (dysbiosis index, DI), and potential deviation in the microbiome from normobiosis. 1 DI is based on 54 DNA probes targeting more than 300 bacterial strains based on their 16 S rRNA sequence in seven variable regions (V3-V9). A DI above 2 shows a microbiota profile that differs from that of the normobiotic reference collection. 1 In addition, the donors and patients completed the following questionnaires before FMT and again for the patients at 3 weeks after FMT: IBS symptom questionnaire (IBS-SQ), IBS-symptom severity scoring system (IBS-SSS), short form of Nepean Dyspepsia Index (SF-NDI) and Bristol stool scale form.
Results: The DI (mean AE SEM) of the donors (1.8 AE 0.23) differed significantly from the patients before FMT (2.7 AE 0.37, p ¼ 0.009) and at 1 week after FMT (2.7 AE 0.38, p ¼ 0.039) but not at 3 weeks after FMT (2.3 AE 0.29, p ¼ 0.1). The profile of a selection of the most important bacteria ( Table 1) showed significant differences in several strains of the gut microbiota between the donors and IBS patients before receiving FMT, which became non-significant after 3 weeks from receiving FMT. The scores of IBS-SQ were significantly reduced during the 3 weeks after receiving FMT; total (p 5 0.0001), nausea (p ¼ 0.001), bloating (p 5 0.0001), abdominal pain (p ¼ 0.0005), constipation (p ¼ 0.01), diarrhea (p 5 0.0001), but not for anorexia (p ¼ 0.09). The total scores of IBS-SSS, SF-NDI and Bristol stool scale were significantly reduced after receiving FMT (p ¼ 0.0004, 0.004 and 0.008, respectively). No adverse effects were reported after FMT.
Conclusion: This is the first study to show the kinetics of microbial community composition in IBS patients following FMT. The results show that FMT helps in restoring alterations in the signals of several strains of the gut microbiota in IBS patients. This suggests that the microbiota profile between donors and patients following FMT has become similar and may have contributed in improving the symptoms and quality of life for these patients. FMT may be used as a treatment for IBS. Contact E-mail Address: suzanne.witt@liu.se Introduction: Irritable Bowel Syndrome (IBS) is a brain gut disorder involving alterations in mucosal barrier function and central pain processing networks. 1 Although it has been proposed that increased gut barrier permeability is related to increased visceral pain, no studies have thus far addressed if peripheral and central alterations are linked in IBS. The objectives of this study were to: (1) identify if changes in gut mucosal barrier function are correlated with changes in brain functional connectivity in the default mode network (DMN), a network associated with self-related processing, and (2) test if this correlation differs in patients with IBS.
Aims & Methods: Colonic biopsies were acquired on 32 women with IBS (mean age 32.6y) and 15 healthy women (HC; mean age 29.7y) and mounted in Ussing chambers to measure mucosal paracellular permability using the 384 Da inert probe 51 chromium (Cr)-EDTA. Symptoms were measured with the IBS Severity Scoring System (IBS-SSS). Resting state fMRI scans were acquired on the same set of subjects using a 3T MRI scanner. The fMRI data were preprocessed using standard procedures and group independent component analysis was used to identify the DMN. Between-group covariate analysis was performed across the whole brain to identify differences in the correlation between peripheral measures of 51 Cr-EDTA permeability and functional connectivity in the DMN.
Results: The 51 Cr-EDTA colonic permeability was significantly higher in IBS (p 5 0.05). The IBS patients' symptom severity was mostly moderate to severe (IBS-SSS mean 342, range 112-480). Significant between-group whole-brain differences in the correlation of 51 Cr-EDTA levels and DMN functional connectivity were observed (p 5 0.05, Family Wise Error correction). While increased 51 Cr-EDTA permeability in both groups was linked to greater connectivity with regions in both ascending and descending pain pathways, the specific regions differed between groups. In IBS, increased permeability correlated to increased connectivity of DMN with posterior insulae, paracentral lobule, periaqueductal gray and anterior cingulate. In HCs, these correlations involved thalamus, sensorimotor cortex, mid-pons, and nucleus raphe magnus. Conclusion: Even though altered DMN connectivity has been reported in chronic pain, 2 this is the first study to demonstrate that peripheral measures of gut barrier function are associated with changes in DMN functional connectivity, demonstrating a link between peripheral and central functions. In IBS, increased colonic mucosal permeability correlated with increased connectivity between distinct brain regions in both the ascending and descending pain pathways with those brain regions that comprise the DMN. The present results suggest that in IBS alterations in the DMN connectivity may be related to alterations in colonic mucosal permeability. Graz/AT, 2 St. Veit An Der Glan/AT Contact E-mail Address: philip.wurm@medunigraz.at Introduction: Fecal microbiota transplantation (FMT) has been investigated in various studies as an alternative approach for the treatment of patients with ulcerative colitis (UC). Results of recent randomized studies are controversial and response rates to FMT vary considerably between studies. So far factors influencing the efficacy of FMT in UC are poorly understood. Aims & Methods: We investigated the microbiota of UC patients treated by repeated FMT and corresponding donors for a specific microbial signature correlating to clinical efficacy of FMT. Microbiota analysis was performed by 16S rRNA gene-based microbiota analysis. 17 patients were treated with repeated FMT (n ¼ 5) in 14-day intervals after an antibiotic pretreatment for 10 days. Fecal suspension were derived from 14 donors; the same donor had to serve for one patient throughout the study. Patients were divided into responder vs. non responder according to a reduction of the total Mayo score of 43 points and remission as a total Mayo score of 52 points at day 90. Results: 59% (10/17) of patients showed a response and 24% (4/17) a remission to FMT. Donors' microbiota structure associated with recipient response had a higher bacterial diversity than donors' microbiota structure, who did not induce response. Furthermore, abundance of Akkermansia muciniphila, as well as unclassified Ruminococcaceae was significantly higher in the donor stools transferred to patients with remission compared with donors leading to non-response.
Disclosure of
Interestingly, engraftment of the donor microbiota was not associated with treatment success, since all recipients' microbiotas, regardless of response, shifted towards the respective donor microbiota. However, microbiota analysis prior to FMT revealed no specific differences in the microbiota structure of responder and non-responder. Conclusion: Taxonomic composition of donor microbiota, especially high abundance of A. muciniphila and unclassified Ruminococcaceae is a major factor for efficacy of FMT in chronic active UC. Selective focus on composition of donor microbiota might increase efficacy of FMT in chronic active UC. regimen. Data were collected at infusion visits. The primary endpoint was disease worsening during follow-up according to worsening in disease-specific composite measures and/or a consensus between investigator and patient leading to major change in treatment. Exploratory subgroup analyses were performed to examine disease worsening within each of the six diagnoses. The non-inferiority margin was set to 15% and power calculations indicated that 394 patients were required in the primary Per Protocol Set (PPS). The primary endpoint was analysed using logistic regression, adjusted for diagnosis and disease duration at baseline. Results: Between 6 October 2014 and 8 July 2016, 481 patients (INX 241, CT-P13 240, Full Analysis Set, FAS) at 40 Norwegian study centres were randomized, received treatment and were followed for 52 weeks. The main demographic and baseline characteristics are shown in the table. Disease worsening occurred in 26.2% and 29.6% of patients in the INX and CT-P13 arms, respectively (PPS). The 95% confidence interval of the adjusted treatment difference (À4.4%) was À12.7 to 3.9, which was within the pre-specified non-inferiority margin. The frequency of disease worsening in each specific diagnosis is shown in the table (exploratory analyses). Changes in the generic disease variables and disease specific composite measures were similar in both arms (table) . The incidence of anti-drug antibodies detected during the study was 17 (7.1%) and 19 (7.9%) in the INX and CT-P13 patients, respectively (FAS). The trough drug levels and the frequencies of reported adverse events including infusion reactions were also similar (data not shown). Data are n (%), mean (SD) or median (2575 percentiles). 95% CI, 95% confidence interval of the adjusted treatment difference. BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; DAS28: Disease Activity Score in 28 joints, CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index; PASI: Psoriasis Area and Severity Index. -0301) is an antisense oligodeoxynucleotide that is complementary to the sequence of the messenger ribonucleic acid (mRNA) transcript of Smad7. It is formulated as a gastro-resistant, delayed release, pH-dependent tablet designed to deliver the active substance in the distal GI tract with negligible systemic exposure and is being evaluated for the treatment of patients with active Crohn's disease. Clinical efficacy has been demonstrated in a phase 2 study. 1 The intent of this phase 1b study is to examine endoscopic improvement and clinical benefit with three different mongersen treatment regimens.
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Aims & Methods: Subjects with active CD (Crohn's Disease Activity Index [CDAI] score of 220-450, total simple endoscopic score for CD [SES-CD] of !7 or ileal disease SES-CD of !4) were randomised to 4, 8 or 12 weeks of mongersen 160 mg daily, followed by an observation period without study drug. Endoscopic and clinical assessments are reported through week 12. Endoscopic assessments at baseline (BL) and week 12 were centrally read. Daily electronic diary records were used to collect CD symptoms. including abdominal pain and soft/loose stool frequency; a clinical evaluation, including CDAI determination, occurred at monthly visits. Results: 63 subjects were enrolled; at BL, mean age was 41.5 years, mean SES-CD was 11.2 and mean CDAI was 294. Mean CD duration was 11.6 years; with 46% having had prior exposure to TNF-therapy; 46% of subjects had involvement distal to the mid transverse colon. 52 subjects had evaluable endoscopies at week 12. Of these subjects, 37% had an endoscopic response, defined as !25% reduction in SES-CD from BL to week 12, with no meaningful difference across treatment groups. Of the subjects with greater endoscopic disease activity at BL (SES-CD 412), 63% had a reduction !25% and 31% had a reduction !50%. Clinical improvement was seen by week 2, with rates of clinical response (CDAI decrease !100), and clinical remission (CDAI 5150) maintained or increased in all three treatment groups over 12 weeks. The highest clinical response (67%) and clinical remission(48%) rates were seen in the 12-week treatment group. Change from BL in CDAI was also higher in the 12-week treatment group, with a mean reduction of 133 points. Further analysis of the clinical improvement criteria showed similar benefit among subjects who had greater BL disease severity based on CDAI (4300), longer duration of CD history (45 years) or history of CD surgery. Adverse event (AE) rates and serious AE rates were low and similar across treatment groups. Mongersen was generally safe and well tolerated with no new safety signals emerging. Conclusion: Oral mongersen resulted in meaningful endoscopic improvement at an early time point (12 weeks Introduction: The IL-23 pathway is implicated in the pathogenesis of Crohn's disease (CD) both genetically and biologically. Aims & Methods: The efficacy and safety of risankizumab (formerly BI 655066), a humanised monoclonal antibody that selectively inhibits IL-23 through specific targeting of the IL-23 p19 subunit, is being assessed in a randomised Phase II study in patients (pts) with moderate-to-severe active CD (NCT02031276). The study has three treatment periods: a 12-week (wk), double-blind, intravenous (IV) induction period (P1); a 14-wk, open-label (OL), IV re-induction/washout period (P2); and a 26-wk OL subcutaneous maintenance period. In P1, pts (N ¼ 121) with clinically active CD (CD Activity Index [CDAI]4220) confirmed by endoscopy (CD Endoscopic Index of Severity [CDEIS]?7;?4 for pts with isolated ileitis) were randomised to either 200 or 600 mg risankizumab or placebo (PBO) at Wks 0, 4 and 8. The primary endpoint was clinical remission (CR; CDAI 5150) at Wk 12. At Wk 12, pts entered P2; here, pts in deep remission (CR þ endoscopic remission) underwent washout and all other pts underwent OL IV re-induction therapy (600 mg risankizumab at Wks 14, 18 and 22). Results: Baseline demographics and disease characteristics were similar between study arms. Mean age was 38.1 yrs and median CDAI and CDEIS scores were 298 and 12; 94% of pts had previously received 41 TNF antagonists. At Wk 12, CR was achieved by 24.4% and 36.6% of pts with 200 and 600 mg risankizumab vs. 15.4% for PBO (p ¼ 0.31 and p ¼ 0.025) and deep remission was achieved by 2.4% and 12.2% of pts with 200 and 600 mg risankizumab vs. 0% for PBO (p ¼ 0.31 and p ¼ 0.016). In pts entering P2 without CR, OL re-induction of PBO pts induced a rate of CR similar to the 600 mg arm in the blinded P1, dose escalation from 200 to 600 mg induced a high CR rate, and re-induction treatment in the 600 mg arm further increased the CR rate in this group at Wk 26 (Table) . No pts with deep remission relapsed during the risankizumab washout phase to Wk 26. AEs were similar between risankizumab and PBO with no doserelated increase in AEs in P1. Risankizumab was well tolerated in P2. Conclusion: Re-induction therapy with 600 mg risankizumab was effective in increasing clinical remission rates further at Wk 26. Overall, risankizumab was well tolerated. In contrast, the anti-TNF fab' fragment certolizumab shows a low healing rate. These observations suggest that besides TNF neutralization, other antibody characteristics contribute to the therapeutic potency. We have previously shown that the Fc region of anti-TNF induces CD206þ regulatory macrophages with wound-healing properties in IBD patients. Here we demonstrate the importance of Fc-receptor signaling for the therapeutic effect of anti-TNF in vivo and in vitro. Furthermore, increasing the Fc binding affinity resulted in improved therapeutic efficacy.
Clinical remission at
Aims & Methods: RAG-/-mice lacking all activating Fc receptors were generated. We constructed defucosylated anti-murine TNF and defucosylated adalimumab. All in vivo studies were performed in the T-cell transfer colitis model. For in vitro studies, T-cell proliferation and CD206þ macrophages percentages were measured in mixed lymphocyte reactions containing human PBMC from healthy donors. Results: Anti-TNF treatment achieved near complete healing of mouse intestines in the T-cell transfer model. However, mice lacking all activating Fcreceptors were completely unresponsive to anti-TNF therapy. In line with our previous human data, colons of wild-type mice treated with anti-TNF contained increased amounts of CD206þ macrophages, but this effect was completely abrogated in Fc-receptor KO mice. Further studies in vitro revealed that blocking Fc-receptor III (CD16) impaired both induction and function of human CD206þ macrophages, suggesting this may be the most prominent receptor mediating anti-TNF effects in humans. Interestingly, affinity for Fc-receptor III can be increased by defucosylation of the Fc region of the antibody. Supporting the idea of a crucial role for Fc receptor binding in anti-TNF efficacy, defucosylation of anti-TNF enhanced the induction of CD206þ macrophages and improved inhibition of T-cell proliferation in vitro. Finally, defucosylated anti-TNF significantly improved therapeutic efficacy in the T-cell transfer model and increased the amounts of CD206þ macrophages in the colon.
Conclusion: Activating Fc-gamma receptors are indispensable for the therapeutic effect of anti-TNF in IBD in vivo. Enhancing the IgG Fc binding affinity of anti-TNF by defucosylation, improved the effectiveness in vivo and in vitro.
Since more than one-third of IBD patients do not respond to induction therapy, enhancing the Fc binding affinity of anti-TNF by defucosylation could be an effective approach to improve clinical outcome. Disclosure of Interest: Geert D'Haens: reports having received consulting and/ or lecture fees from AbbVie and more; however, this will exceed the maximum of 255 characters and is therefore not possible to submit. Interleukin-6 (Il-6), with its context-dependent pro-and anti-inflammatory properties, is known as a key modulator of the inflammatory response in IBD, as well as in other inflammatory diseases and cancer, and therefore regarded as a prominent target for clinical intervention. 1 Sgp130Fc is the natural inhibitor of the soluble interleukin-6 receptor transsignaling responses and therefore inhibits the pro-inflammatory effects of IL-6 while the anti-inflammatory impact of IL-6 via the membrane-bound receptor (so-called classical signaling) is left intact.
Aims & Methods:
We analyzed the effect of transgenically increased sgp130Fc serum levels in DSS-colitis and AOM-DSS induced tumorgenesis. For this purpose we used a mouse model with wild-type mice (all on a C57BL6/N background) (n ¼ 28), mice with genetically increased sgp130Fc levels (n ¼ 34), and wild-type mice that were injected recombinant sgp130Fc once a week (n ¼ 17). The three groups of mice received 3% DSS in the drinking water for 5 days. To induce tumorgenesis in mice with genetically increased sgp130Fc levels and the corresponding wild-type mice, we injected AOM at two different time points and let the mice go through three consecutive cycles (each over 7 days) of 2% DSS in the drinking water.
Results: In the model of DSS colitis, significantly (p 5 0.05) more weight loss but no difference in disease activity was seen in the transgenic mice compared with the wild-type mice. Mice that were injected with recombinant sgp130Fc had significantly (p 5 0.05) lower disease activity compared with the wild-type mice. However, these clinical data could not be supported by histological changes in the tissue since no differences in mucosal disease activity were observed. FACS analysis of colonic lamina propria cells in DSS-colitis showed that the number of macrophages was not increased in the early phase of inflammation (day 4) in mice treated with recombinant sgp130Fc compared with wild-type mice. However, at a later time point (day 8) the level of macrophages increased in transgenic sgp130Fc mice compared with wild-type mice and mice injected with sgp130Fc but remained low in mice treated with recombinant sgp130Fc mice. In the model of AOM-DSS-induced colon cancer, no significant differences could be observed concerning tumor number, tumor load and tumor size in transgenic sgp130Fc mice compared with the wild-type animals.
Conclusion: Although the injection of recombinant sgp130Fc limits the disease activity in DSS-colitis, these changes in clinical outcome are not accompanied by changes in mucosal disease activity. In contrast, the transgenic increase of sgp130Fc leads to an increase in disease activity in the DSS-colitis mouse model, while no significant differences in the histology could be detected. The effect of limited tumorgenesis via injected sgp130Fc could not be seen in the transgenic sgp130Fc mice. Finally, it needs to be pointed out that transgenically elevated serum levels of sgp130Fc have a strikingly different effect on colitis disease activity than temporarily increased sgp130Fc levels.. Vandoeuvre Les Nancy/FR, 2 San Diego, CA/US Contact E-mail Address: peyrinbiroulet@gmail.com Introduction: Of the 5 sphingosine-1-phosphate (S1P) receptor subtypes, activation of 1, 4 and 5 may be involved with decreasing intestinal inflammation and subtypes 2 and 3 with cardiac, pulmonary and tumor-related side effects. Current S1P modulators lack receptor selectivity and are associated with cardiopulmonary side effects. Etrasimod is a next-generation oral S1P modulator with an optimized S1P receptor activity profile currently in Phase 2 clinical development for treating ulcerative colitis (UC). The objective of these studies was to evaluate the receptor profile of etrasimod and its effects in a UC model in SCID mice. Aims & Methods: Agonist (S1P1-5) and antagonist (S1P2-3) human S1P receptor -arrestin recruitment assays were used to determine EC 50 values for etrasimod. EC 50 determinations were performed using 10 concentrations and triplicate determinations made at each test concentration. A recombinant human S1P1 receptor agonist cAMP accumulation assay was developed utilizing the same cell line. Additional studies were performed with rodent S1P1 receptors. In vivo, CD4 þ CD45RB high T cells were isolated from wild-type mice and transferred into SCID mice to induce colon inflammation and pathology reminiscent of human UC. Etrasimod (1 and 3 mg/kg) was administered prophylactically from the day of T-cell transfer until Day 32. The relationship between etrasimod plasma concentrations and lymphocyte counts was explored after oral administration in male BALB/c mice. Results: Using -arrestin assays, etrasimod demonstrated potent activity at the S1P1 receptor with a mean EC 50 of 6.10 nM, and partial activity at S1P4 and S1P5 receptors (EC 50 147 nM and 63% efficacy for S1P4 receptor vs. S1P and EC 50 24.4 nM and 73% efficacy for S1P5 receptor vs. S1P). Etrasimod was inactive at concentrations up to 10 mM in S1P2 or S1P3 assays performed in agonist or antagonist modes. In the S1P1 receptor cAMP accumulation assay, etrasimod was a potent agonist (mean EC 50 0.199 nM). Similar potencies were found for non-human S1P1 receptors. Mice that received CD4þ CD45RB high T cells progressively developed symptoms of colitis compared with mice that received unsorted CD4þ T cells. Prophylactic treatment with 3 mg/kg/day etrasimod and 1 mg/kg/day FTY720 significantly inhibited weight loss and colon inflammation versus vehicle-treated controls. Effective lymphocyte-lowering was shown in normal mice at the same doses.
Conclusion: These data demonstrate potent activity of etrasimod at human and non-human S1P1 receptors, with 24X and 4X respective selectivity over human S1P4 and S1P5 and no activity at human S1P2 or S1P3. Etrasimod was also efficacious in an in vivo model of UC in SCID mice. Based on these results, etrasimod may provide systemic and local immune cell modulation in the treatment of UC by selectively targeting S1P receptor subtypes 1, 4 and 5 while avoiding receptors associated with safety issues. Contact E-mail Address: j.langhorst@kliniken-essen-mitte.de Introduction: The combination of positron emission tomography (PET) with 18Ffluorodeoxyglucose (18F-FDG) with magnetic resonance imaging (MRI) as integrated PET/MRI in one examination is a new cutting-edge technology for the non-invasive assessment of the inflammatory activity in Crohn's disease (CD). In CD a manifestation throughout the gastrointestinal tract is possible. Therefore, a comprehensive diagnostic work-up is recommended. A number of non-invasive biomarkers like Lactoferrin and Calprotectin are increasingly popular and used in all-day patient care.
We aimed to compare the performance of non-invasive biomarkers with PET/MRI and colonoscopy in patients with CD. In every patient a PET/MRI including the maximum standardized uptake value ratio gut/liver (SUVQuot) and a colonoscopy including an endoscopy index (SES-CD) was performed. The PET/MRI was rated as pivotal for the small bowel and colonoscopy for the colon. Lactoferrin (LF; TechLab), CalprotectinIMUN (CalI; Immundiagnostik), CalprotectinCALPREST (CalP; Eurospital), PMN-elastasis (PMN-e; mmundiagnostik), S100A12 (Immundiagnostik) as well as CRP (?0.5 mg/dl) were correlated to the SUVQuot and the SES-CD using nonparametric correlation analyses. Sensitivity, specificity and diagnostic accuracy were calculated using optimized cut-offs. Results: 50 patients (32 female), mean age 43.1 AE 13.4 years (range 20-67) with known CD were included in the study. N ¼ 28 patients showed signs of active disease in colonoscopy and/or PET/MRI, n ¼ 14 patients showed at least one stenosis. SUVQuot was correlated significantly with the SES-CD (r (45) ¼ .43; p ¼ .003) and with LF (r (50) ¼ .32; p ¼ .024) and S100A12 (r (50) ¼ . was 4.1%, mostly due to angulation in a fixed sigmoid colon. Median intubation time was a minute quicker in the EAC arm (p ¼ 0.001). Overall patient comfort scores were similar in both groups but anal intubation was rated as more uncomfortable with EAC. Adverse events were equivalent in both arms with no significant cuff-related adverse events. For insertion and withdrawal times, EAC was non-inferior to SC in both subgroups. Conclusion: This large randomised controlled trial demonstrates that Endocuff-Vision TM significantly improves ADR. This improvement was driven by a large increase in ADR in FOB positive BCSP patients. Endocuff-Vision TM allowed quicker colonic intubation and was non-inferior in all aspects other than discomfort on anal intubation. This study demonstrates that in a population where adenomas are likely to be found the Endocuff-Vision TM improves mucosal visualisation and adenoma detection. The purpose of the study was to obtain safety and performance data for the microwave coagulation modality of the CROMA Electrosurgical System (Creo Medical Ltd, UK) and RS2 polyp resection device to complement existing data and support a CE marking application. 1 Aims & Methods: This study was a dual-centre, non-randomised, prospective, non-comparative, prospective pivotal trial. The primary objective was to assess the safety and efficacy of microwave coagulation of visible blood vessels and the treatment of oozing/actively bleeding vessels (?1mm in diameter) during endoscopic resection of complex colorectal polyps. The secondary objective was the identification and incidence of peri-and post-procedural complications. Patients completed part 1 of the study if vessels were treated with microwave during polypecytomy and part 2 of the study when they attended for endoscopic follow-up at 3-6 months.
Results: A total of 38 patients were screened; one patient declined to participate; 37 patients were enrolled; 31 patients completed Part 1 of the study; 30 patients completed Part 2 of the study. Six patients were withdrawn from the study on completion of their endoscopic procedure; either for clinical reasons (diagnosis of cancer, Â2) or absence of suitable blood vessels for coagulation (Â4). One patient was withdrawn following their telephone follow-up subsequent to a diagnosis of cancer. The majority of participants in the study were male (67.7% vs. 32.3%). Mean age, height, weight and BMI was 66.4y (SD 13.2), 1.7 m (SD 0.1), 79.7 kg (SD 16.9) and 27.7 kg.m 2 (SD 4.9), respectively. There were no protocol violations in the study. Patient compliance with the visit schedule for the study was 100%. Patient recruitment was completed in 8.3 months. A total of 51 blood vessels meeting the required inclusion criteria were treated in Part 1 of the study. The majority of blood vessels, 98% (50/51) were successfully coagulated by the microwave device (95% exact CI 89.6% to 100%). The majority of study patients (30/31, 96.8%) had all blood vessels meeting the study inclusion criteria successfully coagulated (95% exact CI 83.3% to 99.9%). The majority of these blood vessels (29/51, 56.9%) were successfully coagulated at first attempt (95% exact CI 42.3% to 70.7%). One blood vessel could not be coagulated by two applications of microwave energy, but was successfully treated by the use of an endoclip, as per protocol. There were no significant complications or device-related events in the study. Of those patients completing Part 2 of the study, 97% had a completely healed scar at the site of their polypectomy and one patient had some granulation tissue. Five patients displayed small recurrence of 51 cm and one patient had a recurrence of 41 cm (recurrence rate 17%), all easily treatable with further endoscopic therapy.
Conclusion: Microwave coagulation appears to be a safe and easy modality to apply. No serious adverse events were recorded. No disruption of the normal healing process was noted. Small vessels (?1mm in diameter) were successfully treated at a pre-coagulation or bleeding phase using the microwave coagulation. . This study hypothesised that if these initiatives were successful there would initially be a rise in the age-standardised incidence (ASI) of CRC due to the earlier diagnosis of tumours already present in the population, achieved by earlier, more frequent and higher quality colonoscopies. A drop in incidence would then follow this rise, as there would be fewer patients presenting late. In addition, it would be expected that with more widespread and higher-quality colonoscopy, fewer cancers would occur because of the 'preventative' effect of colonoscopy. We hypothesised that the speed and depth of any drop in incidence would reflect the impact of the interventions. We aimed, therefore to compare CRC incidence rates with colonoscopy use (both inside and outside of the screening programme) and emergency presentation rates (as a surrogate for late diagnosis).
LB26 NATIONAL EARLY DIAGNOSIS INITIATIVES AND THEIR
Aims & Methods: Information on all CRCs diagnosed between 2001 and 2014 was extracted from the National Cancer Registration and Analysis Service (NCRAS) and directly age-standardised incidence rates were calculated for each year. In addition, data were taken from Hospital Episode Statistics (HES) on all colonoscopy and flexible sigmoidoscopy procedures undertaken in the English NHS in each financial year between 2001/02 and 2014/15. Emergency presentation rates were derived from linked NCRAS and HES data. Incidence rates of CRC, the use of colonoscopic procedures and emergency presentation rates were then compared.
Results: CRC incidence rates rose steadily in England during the period of the national initiatives, until 2012, when there was a sudden and statistically significant 5.6% reduction. The drop was greatest in men. Over this period the numbers of colonoscopic procedures undertaken more than doubled from 303,790 in 2001/2 to 778,292 in 2014/15. From 2010 onwards, around 7% of these colonoscopies were undertaken as part of the national screening programme. The proportion of cases presenting urgently dropped from 33.6% in 2001 to 23.7% in 2014.
Conclusion: This study demonstrates a change in ASI of CRC, increasing use of colonoscopic procedures and a reduction in emergency presentation rates that all occurred concurrently with national initiatives aimed at improving outcomes through earlier diagnosis. These associations suggest the initiatives have had the intended impact. The ASI changes were greatest in men, which is important as they have been more likely to present with late-stage disease and less likely to engage in screening. We propose that ASI should be a key outcome measure to monitor the impact of national interventions aimed at improving the timing of diagnosis of CRC and the quality of the diagnostic test. Disclosure of Interest: All authors have declared no conflicts of interest. Cheonan/KR, 2 Seoul/KR Contact E-mail Address: dwseoamc@amc.seoul.kr Introduction: Endoscopic ultrasound (EUS)-guided pancreatic cyst ablation (PCA) has been shown to be effective, but long-term durability is not well understood.
Aims & Methods: The aim of this study was to investigate the long-term efficacy and durability of EUS-PCA for pancreatic cystic tumors. In this prospective cohort study, patients with pancreatic cystic lesions (PCLs) underwent EUS-PCA using ethanol with or without paclitaxel. The inclusion criteria were as follows: unilocular or oligolocular cysts without definite communication to the main pancreatic duct; clinically indeterminate pancreatic cystic tumors; and patients who refused surgery or were at high risk. Outcomes included efficacy, safety, and durability of response. Multivariate analysis was used for variables to demonstrate the independent factors related to complete cyst resolution.
Results: A total of 164 patients with pancreatic cysts underwent one (n ¼ 159) or two (n ¼ 5) EUS-PCA procedures, and five patients were excluded from the analysis due to follow-up loss. The median cyst diameter at baseline was 32 mm, and the median level of carcinoembryonic antigen was 157 ng/ml. Presumed clinical diagnoses were mucinous cystic neoplasm in 95 patients, serous cystadenoma in 23 patients, intraductal papillary mucinous neoplasm in 22 patients, and indeterminate cyst in 24 patients. Complete resolution (CR) was achieved in 115 patients (72.2%), partial resolution was achieved in 40 patients, and 13 patients had persistent cysts. Twelve of 13 patients with persistent cysts underwent surgical resection. Procedure-related adverse events occurred in 18 (11%) patients. During further follow-up (median 72 months) of the 106 patients with initial successful CR, only two patients (2%) showed cyst recurrence. Based on multivariate analysis, the absence of septa and non-mucinous cysts predicted cyst resolution. Conclusion: In patients with PCLs, EUS-PCA has an acceptable safety profile, is durable, and is associated with a low rate of recurrence for up to 6 years. Unilocular and non-mucinous cysts predicted CR.
common bile ductmicrolithiasis/stone/sludge) (n ¼ 60) followed by chronic pancreatitis (CP) (n ¼ 25), pancreatic tumour (n ¼ 11) and pancreaticobiliary ascariasis (n ¼ 9). No cause was found in 48 patients. Conclusion: Occult biliary stone/sludge was the predominant cause for IAP followed by CP. EUS is a safe investigation with a high diagnostic yield for determining the aetiology of IAP and an early EUS can influence important therapeutic decisions and prevent further attacks of AP which may occur if a delayed EUS is performed, and thus improve long-term prognosis. An early EUS also has an additional advantage of making an early diagnosis of pancreatic tumours. It also prevents making the wrong diagnosis of sludge as aetiological factor for AP, which may occur in patients undergoing a delayed EUS since sludge may be secondary to AP due to prolonged fasting, total parenteral nutrition or antibiotics like ceftriaxone. Disclosure of Interest: All authors have declared no conflicts of interest.
